Your browser doesn't support javascript.
loading
Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France.
Loubet, Paul; Gaborit, Benjamin; Salpin, Mathilde; Gardeney, Hèlene; Benotmane, Ilies; Systchenko, Thomas.
  • Loubet P; Virulence Bactérienne et Infections Chroniques, University Montpellier, Nîmes, France.
  • Gaborit B; Service des Maladies Infectieuses et Tropicales, CHU Nantes, Nantes, France.
  • Salpin M; Service de Pneumologie, AP-HP, Hôpital Bichat, Paris, France.
  • Gardeney H; Service d'Hématologie, CHU Poitiers, Poitiers, France.
  • Benotmane I; Service de Néphrologie-Dialyse-Transplantation, CHU Strasbourg, Strasbourg, France.
  • Systchenko T; Service d'Hématologie, CHU Poitiers, Poitiers, France.
Hum Vaccin Immunother ; 20(1): 2387221, 2024 Dec 31.
Article en En | MEDLINE | ID: mdl-39143811
ABSTRACT
France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Huésped Inmunocomprometido / Profilaxis Pre-Exposición / COVID-19 Límite: Adult / Aged / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Huésped Inmunocomprometido / Profilaxis Pre-Exposición / COVID-19 Límite: Adult / Aged / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2024 Tipo del documento: Article